BioWorld MedTech

Dec. 8, 2016

Abbott ready to bolt on Alere based on 'damaging business developments'

After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. Read More

MIT team reduces beta amyloid plaques in mice using light therapy

Cures Act sails through Senate in 94-5 landslide

AdvaMed's Trunzo says least burdensome standard revived

EU sliding toward a compliance cliff as regulations advance

Attorney says outcome of hearing on CRISPR patents tough to predict

Abiomed Impella CP gets green light for high-risk PCI treatment

Appointments and advancements

Product briefs

Financings

Other news to note

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...